Valladares-Garrido Mario J, Zeña-Ñañez Sandra, Peralta C Ichiro, Puicón-Suárez Jacqueline B, Díaz-Vélez Cristian, Failoc-Rojas Virgilio E
Vicerrectorado de Investigación, Universidad Norbert Wiener, Lima 15046, Peru.
Hospital Regional Lambayeque, Chiclayo 14012, Peru.
Vaccines (Basel). 2022 May 20;10(5):812. doi: 10.3390/vaccines10050812.
COVID-19 vaccines have achieved a significant reduction in mortality, yet objective estimates are needed in specific settings. We aimed to determine the effectiveness of COVID-19 vaccination at a referral hospital in Lambayeque, Peru. We conducted a retrospective cohort study from February to September 2021. We included hospitalized patients with COVID-19, whose data were stored in NotiWeb, a patient data system of the Peruvian Ministry of Health. We applied a propensity score-weighting method according to baseline characteristics of patients, and estimated hazard ratios (HR) using Cox regression models. Of 1553 participants, the average age was 55 years (SD: 16.8), 907 (58%) were male, and 592 (38%) deceased at 28-day follow-up. Before hospital admission, 74 (4.8%) had been immunized with at least one vaccine dose. Effectiveness against death in vaccinated patients was 50% at 90-day follow-up (weighted HR 0.50, 95% CI 0.28-0.89). Our results support the effectiveness of COVID-19 vaccination against death and provide information after early immunization in Peru.
新冠疫苗已显著降低了死亡率,但在特定环境中仍需要客观评估。我们旨在确定秘鲁兰巴耶克一家转诊医院的新冠疫苗接种效果。我们于2021年2月至9月进行了一项回顾性队列研究。我们纳入了新冠住院患者,其数据存储在秘鲁卫生部的患者数据系统NotiWeb中。我们根据患者的基线特征应用倾向评分加权法,并使用Cox回归模型估计风险比(HR)。在1553名参与者中,平均年龄为55岁(标准差:16.8),907名(58%)为男性,592名(38%)在28天随访时死亡。入院前,74名(4.8%)至少接种过一剂疫苗。在90天随访时,接种疫苗患者的死亡预防效果为50%(加权HR 0.50,95%CI 0.28 - 0.89)。我们的结果支持新冠疫苗接种预防死亡的效果,并提供了秘鲁早期免疫后的信息。